BR0206533A - Composto, composição farmacêutica, e, uso de um composto - Google Patents
Composto, composição farmacêutica, e, uso de um compostoInfo
- Publication number
- BR0206533A BR0206533A BR0206533-9A BR0206533A BR0206533A BR 0206533 A BR0206533 A BR 0206533A BR 0206533 A BR0206533 A BR 0206533A BR 0206533 A BR0206533 A BR 0206533A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- group
- optionally substituted
- pyrrole ring
- heteroaryl group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO". O objetivo da presente invenção é fornecer uma composição para a profilaxia ou tratamento da hepatopatia. [Solução] Uma composição contendo como um ingrediente ativo um composto da fórmula (I), ou um sal, éster ou outro derivado deste farmacologicamente aceitável para a profilaxia ou tratamento da hepatopatia: [em que: A é um anel pirrol; R^ 1^ é um grupo arila ou heteroarila opcionalmente substituído; R^ 2^ é um grupo heteroarila opcionalmente substituido; R^ 3^ representa um grupo da fórmula -X-R^ 4^, em que X é uma ligação simples ou um grupo alquileno, alquenileno ou alquinileno opcionalmente substituído, e R^ 4^ é um grupo cicloalquila substituído, um grupo arila substituído, um grupo heterociclila opcionalmente substituído, um grupo heteroarila opcionalmente substituído, ou -NR^ a^R^ b^, em que cada um de R^ a^ e R^ B^ é um átomo de hidrogênio ou um grupo alquila, alquenila, alquinila, aralquila ou alquilsulfonila; contanto que os ditos substituintes R^ 1^ e R^ 3^ estejam ligados aos dois átomos do dito anel pirrol que são adjacentes ao átomo do anel pirrol ao qual o dito substituinte R^ 2^ está ligado].
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001009629 | 2001-01-18 | ||
PCT/JP2002/000290 WO2002057254A1 (fr) | 2001-01-18 | 2002-01-17 | Compositions destinees a la prevention et au traitement de l'hepatopathie |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0206533A true BR0206533A (pt) | 2003-12-16 |
Family
ID=18877075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0206533-9A BR0206533A (pt) | 2001-01-18 | 2002-01-17 | Composto, composição farmacêutica, e, uso de um composto |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1352906A4 (pt) |
KR (1) | KR20030076612A (pt) |
CN (1) | CN1525968A (pt) |
BR (1) | BR0206533A (pt) |
CA (1) | CA2435141A1 (pt) |
MX (1) | MXPA03006468A (pt) |
WO (1) | WO2002057254A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003252212A1 (en) * | 2002-07-19 | 2004-02-09 | Sankyo Company, Limited | Bicyclic unsaturated tertiary amine compound |
KR20060132698A (ko) | 2004-01-23 | 2006-12-21 | 니리어스 파마슈티컬즈, 인코퍼레이션 | 항균제로 유용한 비스-인돌 피롤 |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2228136A1 (en) * | 1995-08-10 | 1997-02-20 | Merck & Co., Inc. | 2-substituted aryl pyrroles, compositions containing such compounds and methods of use |
EP0871444A4 (en) * | 1995-08-10 | 1999-01-13 | Merck & Co Inc | 2.5 SUBSTITUTED ARYL PYRROL, THE COMPOSITIONS THAT CONTAIN AND THE USE THEREOF |
WO1997016442A1 (en) * | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
US6417202B1 (en) * | 1996-07-11 | 2002-07-09 | Pfizer Inc. | Pyridylpyrrole compounds useful as interleukin-and TNF antagonists |
AU4395399A (en) * | 1998-07-02 | 2000-01-24 | Sankyo Company Limited | Five-membered heteroaryl compounds |
AU4315100A (en) * | 1999-04-28 | 2000-11-17 | Sankyo Company Limited | Preventive or inhibitory agents for hepatopathy |
IL137365A0 (en) * | 1999-07-21 | 2001-07-24 | Sankyo Co | Heteroaryl-substituted pyrrole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
JP2001181187A (ja) * | 1999-12-27 | 2001-07-03 | Sankyo Co Ltd | 5員ヘテロアリール化合物を含有する組成物 |
-
2002
- 2002-01-17 KR KR10-2003-7009471A patent/KR20030076612A/ko not_active Application Discontinuation
- 2002-01-17 BR BR0206533-9A patent/BR0206533A/pt not_active Application Discontinuation
- 2002-01-17 MX MXPA03006468A patent/MXPA03006468A/es unknown
- 2002-01-17 WO PCT/JP2002/000290 patent/WO2002057254A1/ja not_active Application Discontinuation
- 2002-01-17 EP EP02716313A patent/EP1352906A4/en not_active Withdrawn
- 2002-01-17 CN CNA028065484A patent/CN1525968A/zh active Pending
- 2002-01-17 CA CA002435141A patent/CA2435141A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002057254A1 (fr) | 2002-07-25 |
CN1525968A (zh) | 2004-09-01 |
EP1352906A1 (en) | 2003-10-15 |
EP1352906A4 (en) | 2004-06-16 |
MXPA03006468A (es) | 2003-09-22 |
KR20030076612A (ko) | 2003-09-26 |
CA2435141A1 (en) | 2002-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0010520A (pt) | Novos compostos farmaceuticamente ativos | |
BR0111754A (pt) | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica | |
BR0014137A (pt) | Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
BR9806413A (pt) | Composto e uso do mesmo | |
BR9908764A (pt) | Composto e seus sais farmaceuticamente aceitáveis ou ésteres hidrolisáveis in vivo, uso destes, processo para prepará-los, e, composição farmacêutica | |
BR9910971A (pt) | Composto, processos para a preparação de um composto e para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
BRPI0517343A (pt) | derivados de betulina, preparação destes e uso dos mesmos | |
CO5600998A2 (es) | Fluoropirrolidinas como inhibidores de dipeptidil peptidasa | |
BR0206955A (pt) | Ligantes de receptores de canabinóides | |
BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
AR042368A1 (es) | Un compuesto derivado de purina, su uso, un procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
UY27336A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
BR0014116A (pt) | Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica | |
BR0010476A (pt) | Compostos derivados do 4,5,6,7-tetrahidroindazol e seu uso como agentes antitumorais | |
BR9914451A (pt) | Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento | |
BR0009558A (pt) | Composto derivado bicìclico heteroaromático, composição farmacêutica, e, uso de compostos derivados bicìclicos heteroaromáticos | |
BR0306292A (pt) | Composto de éster e uso medicinal do mesmo | |
BRPI0509307A (pt) | compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1 | |
BRPI0507944A (pt) | composição farmacêutica | |
AR018634A1 (es) | Derivados de benzo(b)tiepin-1,1,-dioxido, procedimiento para su preparacion, medicamentos conteniendo estos compuestos, procedimiento para la preparacion de medicamentos y su empleo para la preparacion de medicamentos. | |
ES2163295T3 (es) | Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa. | |
BRPI0817096A8 (pt) | Análogo de tiazolidinodiona e composição farmacêutica que o compreende | |
BRPI0417947A (pt) | composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica | |
BRPI0409241A (pt) | compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |